anti-CD19 CAR T-cell therapy (EXUMA Biotech)

N/A

Report date: 2026/04/24 15:37:20

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (EXUMA Biotech)

Drug Alias Namein vivo engineered anti-CD19 CAR T-cell therapy GCAR (EXUMA Biotech)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesExuma Biotech Corp

China Registration ClassN/A

Develop Information

Active CompaniesExuma Biotech Corp

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A